Clinical Trial Update: Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety and immunogenicity of Plasmodium vivax circumsporozoite protein–derived synthetic peptides formulated with two ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria
• Plasmodium Vivax Malaria

Drugs mentioned

• Plasmodium vivax CSP-derived synthetic peptides

Snippet

Sponsor: Malaria Vaccine and Drug Development Center | Conditions: Malaria, Vivax | Phase 1 | Status: COMPLETED